See more : EVgo, Inc. (EVGOW) Income Statement Analysis – Financial Results
Complete financial analysis of SAB Biotherapeutics, Inc. (SABS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SAB Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Norwegian Block Exchange AS (NBX.OL) Income Statement Analysis – Financial Results
- Sutter Gold Mining Inc. (SGMNF) Income Statement Analysis – Financial Results
- Melbana Energy Limited (MAY.AX) Income Statement Analysis – Financial Results
- Hwa Create Corporation (300045.SZ) Income Statement Analysis – Financial Results
- Nuvectis Pharma, Inc. (NVCT) Income Statement Analysis – Financial Results
SAB Biotherapeutics, Inc. (SABS)
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.24M | 23.90M | 60.88M | 55.24M | 3.44M |
| Cost of Revenue | 3.75M | 3.29M | 1.65M | 0.00 | 0.00 |
| Gross Profit | -1.51M | 20.61M | 59.22M | 55.24M | 3.44M |
| Gross Profit Ratio | -67.28% | 86.23% | 97.28% | 100.00% | 100.00% |
| Research & Development | 16.52M | 36.44M | 57.18M | 27.91M | 8.02M |
| General & Administrative | 23.80M | 16.38M | 17.09M | 6.77M | 4.10M |
| Selling & Marketing | -3.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.05M | 16.38M | 17.09M | 6.77M | 4.10M |
| Other Expenses | 0.00 | -23.90M | -60.88M | 4.00K | 2.59K |
| Operating Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Cost & Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Interest Income | 584.97K | 71.07K | 23.12K | 26.13K | 113.13K |
| Interest Expense | 315.28K | 301.58K | 294.46K | 469.15K | 428.48K |
| Depreciation & Amortization | 3.75M | 3.29M | 1.65M | 548.18K | 323.41K |
| EBITDA | -38.08M | -15.12M | -15.20M | 21.14M | -8.23M |
| EBITDA Ratio | -1,700.56% | -113.62% | -19.24% | 38.26% | -239.25% |
| Operating Income | -38.08M | -28.92M | -13.39M | 20.56M | -8.67M |
| Operating Income Ratio | -1,700.56% | -120.97% | -22.00% | 37.22% | -252.01% |
| Total Other Income/Expenses | -4.12M | 10.20M | -3.75M | -439.02K | -312.75K |
| Income Before Tax | -42.19M | -18.72M | -17.14M | 20.12M | -8.99M |
| Income Before Tax Ratio | -1,884.50% | -78.29% | -28.16% | 36.42% | -261.09% |
| Income Tax Expense | 0.00 | 25.63K | 299.95K | 473.15K | 431.07K |
| Net Income | -42.19M | -18.74M | -17.44M | 20.12M | -9.42M |
| Net Income Ratio | -1,884.50% | -78.40% | -28.66% | 36.42% | -273.62% |
| EPS | -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
| EPS Diluted | -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
| Weighted Avg Shares Out | 5.52M | 4.35M | 2.73M | 2.54M | 43.47M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.35M | 2.73M | 2.70M | 43.47M |
Moncef Slaoui Joins Medicxi
Source: https://incomestatements.info
Category: Stock Reports